Related Experiment Video

Updated: Jun 21, 2026

Development of a Negative Selectable Marker for Entamoeba histolytica
06:05

Development of a Negative Selectable Marker for Entamoeba histolytica

Published on: December 12, 2010

12.5K

Flucofuron as a Promising Therapeutic Agent against Brain-Eating Amoeba

Javier Chao-Pellicer1,2,3, Iñigo Arberas-Jiménez1,2, Ines Sifaoui1,2,3

  • 1Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias, Universidad de La Laguna, Avda. Astrofísico Fco. Sánchez, S/N, 38203 San Cristóbal de La Laguna, Spain.

ACS Infectious Diseases
|May 17, 2024
PubMed

Insights

Flucofuron shows promise for treating primary amoebic meningoencephalitis (PAM), a rare brain infection. This drug candidate effectively targets Naegleria fowleri, including resistant stages, offering new hope for this devastating disease.

Area of Science:

  • Neuroparasitology
  • Drug Discovery
  • Medicinal Chemistry

Background:

  • Primary amoebic meningoencephalitis (PAM) is a rare, severe, and often fatal infection of the brain.
  • Caused by the amoeba Naegleria fowleri, PAM lacks standardized therapeutic protocols.
  • There is an urgent need for effective treatments against N. fowleri.

Purpose of the Study:

  • To identify potential therapeutic agents for PAM from a known compound library.
  • To evaluate the efficacy of identified compounds against Naegleria fowleri.
  • To explore the mechanism of action of promising drug candidates.

Main Methods:

  • Screening of the Medicines for Malaria Venture (MMV) Global Health Priority Box (240 compounds).
  • In vitro testing of compound efficacy against Naegleria fowleri trophozoites and cysts.
  • Determination of inhibitory concentrations (IC50) for active compounds.
  • Analysis of metabolic events induced by the lead compound to infer cell death pathways.

Main Results:

  • Flucofuron demonstrated significant efficacy against Naegleria fowleri trophozoites (IC50 values between 2.47-2.58 μM).
  • Flucofuron was also effective against the resistant cyst stage (IC50: 0.88 μM).
  • Metabolic profiling suggested flucofuron induces apoptosis in N. fowleri.

Conclusions:

  • Flucofuron is a promising drug candidate for treating primary amoebic meningoencephalitis.
  • Drug repurposing offers a viable strategy for developing treatments for neglected diseases like PAM.
  • Further investigation into flucofuron's efficacy and safety is warranted.
Keywords:
Global Health Priority BoxNaegleria fowlerichemotherapyflucofuronprogrammed cell death

More Related Videos

Complementary Use of Microscopic Techniques and Fluorescence Reading in Studying Cryptococcus-Amoeba Interactions10:56

Complementary Use of Microscopic Techniques and Fluorescence Reading in Studying Cryptococcus-Amoeba Interactions

Published on: June 22, 2019

6.3K
Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos11:20

Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos

Published on: May 12, 2020

6.5K

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Pharmaceutical Poisoning: Treatment Strategies01:26

Pharmaceutical Poisoning: Treatment Strategies

Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
Amebiasis01:28

Amebiasis

Entamoeba histolytica, a protozoan parasite, is responsible for intestinal and extraintestinal amebiasis. Though a significant proportion of infections remain asymptomatic, approximately 50 million individuals annually are estimated to present with clinical disease, resulting in up to 100,000 deaths globally. The disease burden is disproportionately high in regions with lower socioeconomic status, such as parts of India, Africa, Mexico, and Latin America.Etiology and TransmissionThe infective...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...